Complete Genomics and Basepair™ Announce Technology Integration Partnership

November 03, 2023 12:00 AM AEDT | By Cision

Complete Genomics and Basepair™ Announce Technology Integration Partnership — Image source: Kalkine Media

Recent News

Incentivizing Long-Term Value Creation

Gold set to glitter again as dollar fightback to fade, fed rate cuts i...

Veolia and MassBio Partner to Accelerate the Deployment of Environment...

Grocers Make a World of Difference on Earth Day

SAN JOSE, Calif. and NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Complete Genomics and Basepair, Inc today announced a technology integration partnership to accelerate the analysis and interpretation of genomic data generated by Complete Genomics' DNBSEQ^TM sequencing platforms*. The partnership gives Complete Genomics' customers the ability for seamless access to Basepair's bioinformatics platform deployed on Amazon Web Services (AWS) and use its easy-to-use point & click user interface to launch and orchestrate NGS workflows in the cloud, either by provisioning in their own accounts or via Basepair's hosted service. Users of the new service will also receive preferential commercial terms to run industry standard secondary analysis tools and pipelines for NGS analysis and interactive visualization, providing Complete Genomics with a secure, reproducible, cost-effective, and scalable cloud solution for their customers.

"This commitment encompasses not only the creation of sequencers for our customers, but also the joint provision of comprehensive analytical tools for securely interpreting sequencing data," said Rob Tarbox, Complete Genomics' Vice President of Product and Marketing. "Partnering with Basepair enables our customers to connect their own AWS accounts, taking a platform approach to bioinformatics that doesn't just translate to enhanced data security and integrity, but also reduces cloud costs, making the process more efficient and seamless."

"Our partnership with Basepair is another way for Complete Genomics to make our customer experience more seamless at all stages of the NGS workflow," Tarbox said.

"It's long been the holy grail of genomics to deliver a seamless sample to answer experience for scientists and clinicians," Basepair's CEO & Founder, Amit Sinha, said. "Today's announcement brings us one step closer to that vision becoming a reality. By enabling Complete Genomics customers to more easily derive value and knowledge from the data generated with their instruments and in a way that eliminates data movement, we will finally be in a position as an industry to unlock the full potential of NGS data."

About Complete Genomics
Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions*. It has been at the forefront of high throughput sequencing technology development since its inception in 2005. Our products have powered over 6,200 publications across a wide array of applications. To learn more, visit www.completegenomics.com.

* For Research Use Only. Not for use in diagnostic procedures.

About Basepair™
Basepair Inc is a market leading point & click bioinformatics company focused on unlocking the full potential of next generation sequencing (NGS) technology. Its SaaS platform abstracts away the DevOps normally required to manage data and run analyses on AWS, yet provisions inside a customer's own AWS account to avoid data movement and improve security & compliance. The resulting democratization of NGS analysis and visualization reduces the downstream bottlenecks that can often slow down R&D projects, accelerating time to scientific and diagnostic insight. To learn more, visit www.basepairtech.com.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.